Paper16809727
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Perez EA and 9 others. J Clin Oncol, 2006. Cited by 362 papers, by iCite.
Cite this record
ConductScience Library. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. Papers, record 16809727. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16809727
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
- PubMed
- Publication types
- Evaluation Study, Journal Article, Multicenter Study, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Genes, erbB-2 | Major topic |
| Immunohistochemistry | Major topic |
| In Situ Hybridization, Fluorescence | Major topic |
| Antibodies, Monoclonal | |
| Antibodies, Monoclonal, Humanized | |
| Biomarkers, Tumor | |
| Chemotherapy, Adjuvant | |
| Female | |
| Humans | |
| Laboratories | |
| Patient Selection | |
| Predictive Value of Tests | |
| Reproducibility of Results | |
| Trastuzumab |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA25224 | NCI NIH HHS | United States | R10CA025224 | PubMed and NIH | NIH RePORTER |
| U10CA025224 | NIH | NIH RePORTER |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 17664462 | The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: a United Kingdom National External Quality Assessment Service/Italian Network for Quality Assessment of Tumor Biomarkers pilot experience. | https://conductscience.org/library/papers/17664462 |
Source PubMed
Cited by145
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 362 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42882335 | Detection Strategies for HER2 and miR-21 in Breast Cancer: Current Approaches and Future Perspectives- Hybrid Systematic Review and Bibliometric Mapping. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42882335 | PubMed |
| 41402571 | HER2 expression in breast cancer: evidence gaps and challenges. | NPJ Precis Oncol | 2025 | https://conductscience.org/library/papers/41402571 | PubMed |
| 41296586 | Challenges & recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement. | Indian J Med Res | 2025 | https://conductscience.org/library/papers/41296586 | PubMed |
| 39707103 | Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/39707103 | PubMed |
| 39470030 | Ultrasound Radiomics for the Prediction of Breast Cancers with HER2-Zero, -Low, and -Positive Status: A Dual-Center Study. | Technol Cancer Res Treat | 2024 | https://conductscience.org/library/papers/39470030 | PubMed |
| 38515821 | Hormone receptor conversion in metastatic breast cancer. | Rep Pract Oncol Radiother | 2023 | https://conductscience.org/library/papers/38515821 | PubMed |
| 38234171 | Machine learning-based model constructed from ultrasound radiomics and clinical features for predicting HER2 status in breast cancer patients with indeterminate (2+) immunohistochemical results. | Cancer Med | 2024 | https://conductscience.org/library/papers/38234171 | PubMed |
| 37562195 | Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer. | ESMO Open | 2023 | https://conductscience.org/library/papers/37562195 | PubMed |
| 37350943 | A comparative study of gastric adenocarcinoma HER2 IHC phenotype and mass spectrometry-based quantification. | Front Oncol | 2023 | https://conductscience.org/library/papers/37350943 | PubMed |
| 36627895 | Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. | Cancer Drug Resist | 2022 | https://conductscience.org/library/papers/36627895 | PubMed |
| 36030496 | Refining the definition of HER2-low class in invasive breast cancer. | Histopathology | 2022 | https://conductscience.org/library/papers/36030496 | PubMed |
| 35954438 | Targeted Approaches to HER2-Low Breast Cancer: Current Practice and Future Directions. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35954438 | PubMed |
| 35458972 | Fine-Tuned DenseNet-169 for Breast Cancer Metastasis Prediction Using FastAI and 1-Cycle Policy. | Sensors (Basel) | 2022 | https://conductscience.org/library/papers/35458972 | PubMed |
| 35284307 | The prognostic effect of HER2 heterogeneity and YAP1 expression in HER2 positive breast cancer patients: a retrospective study. | Gland Surg | 2022 | https://conductscience.org/library/papers/35284307 | PubMed |
| 35223134 | A Novel Data Analytics-derived Metric (Nearest Cluster Distance) Is Easily Implemented in Routine Practice and Correctly Identifies Breast Cancer Cases for Quality Review. | J Pathol Inform | 2022 | https://conductscience.org/library/papers/35223134 | PubMed |
| 35208385 | Deep Learning-Enabled Technologies for Bioimage Analysis. | Micromachines (Basel) | 2022 | https://conductscience.org/library/papers/35208385 | PubMed |
| 35171393 | Blood Vessel Detection Algorithm for Tissue Engineering and Quantitative Histology. | Ann Biomed Eng | 2022 | https://conductscience.org/library/papers/35171393 | PubMed |
| 34868360 | mRNA expression of specific HER ligands and their association with clinical outcome in patients with metastatic breast cancer treated with trastuzumab. | Oncol Lett | 2022 | https://conductscience.org/library/papers/34868360 | PubMed |
| 34720807 | Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet. | Breast Care (Basel) | 2021 | https://conductscience.org/library/papers/34720807 | PubMed |
| 34679544 | Comparison of BSGI and MRI as Approaches to Evaluating Residual Tumor Status after Neoadjuvant Chemotherapy in Chinese Women with Breast Cancer. | Diagnostics (Basel) | 2021 | https://conductscience.org/library/papers/34679544 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16809727
GET https://conductscience.org/api/papers/v1/16809727/cited_by?page=2